IDT and Ansa are joining forces to empower customers with sequence-perfect constructs up to 50 kb, expanding IDT's synthetic ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...

Integrated DNA Technologies collaborates with Ansa Biotechnologies to expand capabilities to IDT’s synthetic biology portfolio: Sunnyvale Saturday, January 17, 2026, 14:00 Hrs [ ...

Genetic medicines such as cell and gene therapies and mRNA vaccines offer extraordinary promise for treating a variety of diseases, including genetic disorders, cancer, and autoimmune diseases. These ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA manufacturing, today announced the launch of ENFINIA™ Plasmid DNA, a faster, cost-effective solution for clonal synthesis ...

Founding CEO Thomas Ybert transitions to Chief Scientific Officer role to underscore company’s ongoing commitment to scientific discovery and innovation PARIS & DALY CITY, Calif.--(BUSINESS WIRE)--DNA ...

Demand for synthetic DNA is growing across multiple industries including cell and gene therapy development and biomanufacturing. Coupled with that growth is a need for genetic constructs that can, in ...

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B round of financing that will be used to expand the company’s DNA synthesis production capacity in the U.S. The San ...

A Northwestern Medicine study has revealed a previously unknown connection between two fundamental cellular processes, ...